Friday, September 01, 2017 7:04:24 AM
Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek
STAMFORD, Conn., Aug. 31, 2017(GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at PAINWeek, to be held September 5-9, 2017 in Las Vegas, NVand the American Association of Nurse Anesthetists (AANA) Nurse Anesthesia Annual Congress, to be held September 8-12, 2017 in Seattle, WA.
Presentations will include clinical trial data for CR845, Cara's first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
PAINWeek
Details for the presentations are as follows:
CR845 Poster Presentation:
Poster Title: "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the
Hip or Knee"Poster Number: 101Date/ Time: Thursday, September 7, 2017; 6:30-8:30 p.m. PT
Satellite Symposium:
Presentation Title: "A Potential New Path of Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)"Date/ Time: Friday, September 8, 2017; 12:30 - 1:30 p.m. PTModerator: Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara TherapeuticsFaculty: Michael J. Brennan, M.D., Medical Director, the Pain Center of Fairfield; Senior Attending Physician, Department of Medicine, Bridgeport Hospital;
Associate Director, Chronic Pain and Recovery Program, Silver Hill Hospital
For information about PAINWeek, visit http://www.painweek.org/.
AANA Nurse Anesthesia Annual Congress
Details for the satellite symposium are as follows:
Presentation Title: "A Potential New Path of Pain Relief"Date/ Time: Sunday, September 10, 2017; 4:00 - 5:00 p.m. PTSpeakers: Jackie Rowles, D.N.P., M.B.A., C.R.N.A., A.N.P.-B.C., D.A.A.P.M., F.A.A.N., Director, DNP Nurse Anesthesia Program, Marian University; Associate
Professor, Leighton School of Nursing; Clinical Instructor, College of Osteopathic Medicine; Adjunct Faculty, Nurse Anesthesia Pain Management Fellowship,
Texas Christian University Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics
For information about AANA, visit http://aana2017.com/. ;
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 michael@sternir.com MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com
http://ir.caratherapeutics.com/releasedetail.cfm
Recent CARA News
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:45:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:24:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:19:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:10:56 PM
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/04/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:50:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 10:15:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 10:13:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 10:10:31 PM
- Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/12/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:34:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:32:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:30:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:28:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 09:26:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:59:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 08:26:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:19:02 PM
- Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 12:10:29 PM
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM